Jennifer L. Good
President & CEO at Trevi Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Trevi Therapeutics Inc., 3 years.
Trevi Therapeutics Inc.
Director · President & CEO
Rhythm Pharmaceuticals Inc.
Director
Chief executive roles
Trevi Therapeutics Inc.
· President & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 21, 2025 | Trevi Therapeutics Inc. | Option exercise | +5,263 | $1.43 | $7,526 |
| Mar 21, 2025 | Trevi Therapeutics Inc. | Open-market sale | −5,263 | $6.58 | $34,631 |
| Sep 17, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +15,000 | $22.93 | $343,950 |
| Sep 17, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +9,250 | $21.37 | $197,673 |
| Sep 17, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +7,501 | $18.99 | $142,444 |
| Sep 17, 2024 | Rhythm Pharmaceuticals Inc. | Open-market sale | −31,751 | $52.40 | $1,663,752 |
| Sep 9, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +12,900 | $22.93 | $295,797 |
| Sep 9, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +4,305 | $21.37 | $91,998 |
| Sep 9, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +1,736 | $18.99 | $32,967 |
| Sep 9, 2024 | Trevi Therapeutics Inc. | Option exercise | +1,840 | $1.43 | $2,631 |
| Sep 9, 2024 | Rhythm Pharmaceuticals Inc. | Option exercise | +18,300 | $4.15 | $75,945 |
| Sep 9, 2024 | Trevi Therapeutics Inc. | Open-market sale | −1,840 | $3.04 | $5,594 |
| Sep 9, 2024 | Rhythm Pharmaceuticals Inc. | Open-market sale | −37,241 | $50.45 | $1,878,808 |
| Sep 6, 2024 | Trevi Therapeutics Inc. | Option exercise | +4,219 | $1.43 | $6,033 |
| Sep 6, 2024 | Trevi Therapeutics Inc. | Open-market sale | −4,219 | $3.03 | $12,784 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.